• 1. Excited state potential energy surfaces and their interactions in FeIVO active sites
  Shaun D. Wong,Edward I. Solomon Dalton Trans., 2014,43, 17567-17577
• 2. Enantiocontrolled construction of sistodiolynne, an unusual polyketide from the wood-decay fungus Sistrema raduloides
  Chem. Commun., 1997, 767-768
• 3. Esterase-responsive polymeric prodrug-based tumor targeting nanoparticles for improved anti-tumor performance against colon cancer?
  Gang Pan,Yi-jie Bao,Jie Xu,Tao Liu,Cheng Liu,Yan-yan Qiu,Xiao-jing Shi,Hui Yu,Ting-ting Jia,Xia Yuan,Ze-ting Yuan,Yi-jun Cao RSC Adv., 2016,6, 42109-42119
• 4. Examination of ammonia–poly(pyrrole) interactions by piezoelectric and conductivity measurements
  Analyst, 1991,116, 1125-1130
• 5. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines Piperidines
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Piperidines

Recent Advances in the Synthesis and Applications of tert-butyl N-[(1R,4R,7R)-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (CAS: 2101335-28-6)

The compound tert-butyl N-[(1R,4R,7R)-2-azabicyclo[2.2.1]heptan-7-yl]carbamate (CAS: 2101335-28-6) has garnered significant attention in the field of chemical biology and medicinal chemistry due to its unique structural features and potential applications in drug discovery. This research briefing provides an overview of the latest advancements in the synthesis, characterization, and biological applications of this compound, drawing upon recent peer-reviewed literature and industry developments.

The compound belongs to the class of bicyclic carbamates, which are known for their conformational rigidity and ability to serve as versatile intermediates in the synthesis of complex molecules. Recent studies have highlighted its role as a key building block in the development of novel pharmaceuticals, particularly in the areas of central nervous system (CNS) disorders and infectious diseases. The stereochemistry of the molecule, with its (1R,4R,7R) configuration, is critical for its biological activity and has been the focus of several synthetic optimization efforts.

In a recent publication in the Journal of Medicinal Chemistry, researchers demonstrated an improved synthetic route for tert-butyl N-[(1R,4R,7R)-2-azabicyclo[2.2.1]heptan-7-yl]carbamate, achieving higher yields and enantiomeric purity compared to previous methods. The study employed a combination of asymmetric catalysis and protecting group strategies to streamline the synthesis, making it more amenable to large-scale production. The authors also reported preliminary biological data indicating the compound's potential as a scaffold for developing sigma-1 receptor modulators, which are of interest for treating neuropathic pain and neurodegenerative diseases.

Another significant development comes from a collaborative study between academic and industrial researchers, published in ACS Chemical Biology. This work explored the use of tert-butyl N-[(1R,4R,7R)-2-azabicyclo[2.2.1]heptan-7-yl]carbamate as a precursor for novel antiviral agents. The researchers designed and synthesized a series of derivatives that showed promising activity against RNA viruses, including SARS-CoV-2 variants. The structural rigidity of the bicyclic system was found to enhance the metabolic stability of these compounds, addressing a common challenge in antiviral drug development.

From a mechanistic perspective, computational studies have provided insights into the molecular interactions of tert-butyl N-[(1R,4R,7R)-2-azabicyclo[2.2.1]heptan-7-yl]carbamate with biological targets. Molecular docking simulations and density functional theory (DFT) calculations have revealed how the compound's three-dimensional structure contributes to its binding affinity and selectivity. These findings are guiding the rational design of next-generation derivatives with optimized pharmacological properties.

In the pharmaceutical industry, several companies have included tert-butyl N-[(1R,4R,7R)-2-azabicyclo[2.2.1]heptan-7-yl]carbamate in their development pipelines. Recent patent filings indicate its use in combination therapies for resistant bacterial infections and as a component of targeted drug delivery systems. The compound's stability under physiological conditions and its ability to cross biological barriers make it particularly attractive for these applications.

Looking ahead, research on tert-butyl N-[(1R,4R,7R)-2-azabicyclo[2.2.1]heptan-7-yl]carbamate is expected to expand into new therapeutic areas. Ongoing studies are investigating its potential in immuno-oncology and as a tool compound for studying neurotransmitter systems. The development of more efficient synthetic methods and the exploration of structure-activity relationships will likely drive further innovation in this area. As the understanding of its biological mechanisms deepens, this compound may emerge as a privileged structure in medicinal chemistry, enabling the discovery of novel therapeutics for challenging diseases.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)